dm+d

Unassigned

New Medicines

Alzheimer's disease

Information

New molecular entity
Amgen
Amgen

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Jul 19Amgen and Novartis are working with investigators to wind up the trials due to weak data from interim analysis that suggest the risks of treatment are not outweighed by the benefits due to worsening of some measures of cognitive function [8].

Category

BACE1-protein-inhibitor. BACE-1 is an aspartyl protease which cleaves amyloid precursor protein to form that N-terminus of Aβ, the major constituent of amyloid plaques.
Alzheimer's disease is the most common form of dementia, accounting for around 50% of cases. It is estimated to affect 496,000 people in the UK. Dementia affects 5.4% of the population over the age of 65, and prevalence increases with age [1].
Alzheimer's disease
Oral